Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT06054737
Other study ID # C1688
Secondary ID
Status Active, not recruiting
Phase
First received
Last updated
Start date September 25, 2023
Est. completion date September 30, 2024

Study information

Verified date December 2023
Source CEN Biotech
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The aim of this clinical trial is to assess the efficacy of the balneotherapy program (therapeutic orientation: Phlebology) in terms of chronic venous disease improvement and related quality of life, in patients presented with advanced chronic venous insufficiency (i.e., with C4-C5 of severity classification). The multicenter randomized controlled trial (RCT) "Thermes & Veines" that aimed at evaluating balneotherapy in patients with advanced chronic venous insufficiency is considered as the reference study. The French National Academy of Medicine encourages the re-use of data of published RCT when available. In this context, the current study is designed as a single-arm prospective study with indirect comparison using propension score. The Control group consists of the 197 patients which were allocated to the Control group of the "Thermes & Veines". All patients enrolled in the current study benefit of 18-days of spa treatment with Mineral Water of Royat, and examination with vascular practitioner at enrollment and 6 months after the beginning of spa treatment.


Description:

Chronic Vascular Disease (CVD) related quality of life and symptoms, as well as skin trophic changes from baseline are assessed at 6 months. Variations from baseline are compared in Control and Spa treatment groups. The indirect comparison methodology is based on the reuse of individual data from a "control" group and adjustment after calculating the propensity score.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 70
Est. completion date September 30, 2024
Est. primary completion date June 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: - Primary or post-thrombotic CVD with confirmed diagnosis by by duplex ultrasound examination (last available exam); - With CVI classified as C4a, C4b, or C5) - Available for balneotherapy program within the 2 next months - With health insurance affiliation. Exclusion Criteria: - Active venous thrombosis, recent or ongoing erysipelas, peripheral arterial pathology (ankle brachial index < 0.70). - Walking difficulty - Neurologic diseases of the lower limbs - Presenting or likely to present a contraindication to thermal treatments, with planned surgery; - Having already benefited from a thermal treatment whatever the indication during the last 6 months - Chronic infectious disease, cancer, heart, kidney or liver failure; - Pregnant, breastfeeding women or women planning a pregnancy within the year; - Persons deprived of their liberty or subject to psychiatric care or subject to a measure of legal protection or unable to express their consent; - Patient likely to not respect the protocol or not to be able to attend the visits, particularly given the study follow-up; - Living at more than 30 minutes from the thermal site or who cannot be accommodated less than 30 minutes from the thermal site; - Already included in a clinical trial or in the exclusion period of a clinical trial.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
SPA THERAPY
Balneotherapy program Four balneotherapy sessions per day, 6 days a week during 3 weeks The balneotherapy sessions included: 10- minute walking session in a specially designed pool with tracks in semideep (80 cm) cool (30°C) water (training of muscle pump function under water compression); 20-minute whirlpool bath session with automatic air or submarine bath if hypodermis (aimed at relaxation and mobilization of the superficial skin volume flow); followed by a 10-minute hydrojet bath (2 sessions) with customized underwater strong massaging jets (mobilization and softening of the sclerotic subcutaneous tissues); Fresh thermal water compresses at 24°C. The cool temperature of the compresses also has an analgesic and decongestant effect. This treatment is carried out last and is followed by a rest for a total duration of 60 minutes

Locations

Country Name City State
France Thermes de Royat Royat Auvergne

Sponsors (2)

Lead Sponsor Collaborator
CEN Biotech TOWN HALL OF ROYAT

Country where clinical trial is conducted

France, 

References & Publications (1)

Carpentier PH, Blaise S, Satger B, Genty C, Rolland C, Roques C, Bosson JL. A multicenter randomized controlled trial evaluating balneotherapy in patients with advanced chronic venous insufficiency. J Vasc Surg. 2014 Feb;59(2):447-454.e1. doi: 10.1016/j.jvs.2013.08.002. Epub 2013 Oct 15. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Changes from baseline in CIVIQ-2 score at 6 months The Chronic Venous Insufficiency Quality of Life Questionnaire (CIVIQ) is a disease-specific instrument to measure the impact of chronic venous insufficiency on patients' lives. CIVIQ-2 or CIVIQ-20 is a self-administered questionnaire that consists in 20 questions of the CIVIQ result in a global score. All questions have a 5-point response category, with higher scores reflecting more severe impairment. The CIVIQ-20 score ranges from 20 (minimal impact) to 100 (maximal impact). Baseline (D1) and final (6 months)
Secondary Changes from baseline in Quality of Life at 6 months Quality of life is measured using the generic EUROQOL (EQ-5D-3L) questionnaire. The EQ-5D-3L descriptive system comprises the following five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: no problems, some problems, and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results into a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state). Baseline (D1) and final (6 months)
Secondary Changes from baseline in 0-100 VAS leg pain related to chronic venous insufficiency at 6 months Pain intensity is measured using a 0 (no pain)-100 (Worse pain) Visual Analogic Scale (VAS). Baseline (D1) and final (6 months)
Secondary Frequency of adverse events throughout the study Adverse events are described using MedDRA and each event frequency is calculated. From inclusion to the final visit at 6 months]
Secondary Participants' satisfaction with the spa therapy program at the end of the program and at 6 months Opinion of the patient is measured using a 5-point Likert scale ranging from 1 ("not at all satisfied") to 5 ("very satisfied") 20 days and 6 months
Secondary Medical-economic impact of the spa therapy program at 6 months EQ-5D-3L score at 6 months and frequency of adverse events related to chronic venous insufficiency.
scores ranges from -0.541 (higher impact of health on quality of life) to 0.982 (lower impact of health on quality of life)
6 months
See also
  Status Clinical Trial Phase
Completed NCT04758728 - Adrenaline Reduces Ecchymoses and Hematomas and Improves Quality of Life After Classic Saphenous Vein Stripping N/A
Completed NCT04180137 - Management of Endothelial Dysfunction in Patients With Chronic Venous Insufficiency After Endovenous Surgical Procedure N/A